P1678ASSOCIATION OF EPIDERMAL GROWTH FACTOR(EGF) AND EGF RECEPTOR POLYMORPHISMS WITH END STAGE RENAL DISEASE AND ACUTE RENAL ALLOGRAFT REJECTION IN KOREAN POPULATION

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Sunwoo Kang ◽  
Byeong Woo KIm
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
End Stage Renal Disease ◽  
Allograft Rejection ◽  
Renal Allograft ◽  
Egfr Gene ◽  
Acute Renal Allograft Rejection ◽  
Epidermal Growth ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background and Aims Epidermal growth factor (EGF) has been found to be associated with development and repair mechanisms of several renal diseases. In this study, we hypothesized that single nucleotide polymorphisms (SNPs) of the EGF or its receptor genes might have association with end stage renal disease (ESRD) or acute renal allograft rejection (AR) in Korean patients. Method 347 recipients of the first renal transplants for ESRD including 63 AR patients among them and 289 healthy adults were included in the study. Five EGF gene SNPs (rs11568835, rs11568943, rs2237051, rs11569017, rs3756261) and four EGFR gene SNPs (rs1140475, rs2293347, rs1050171, rs6965469) were analyzed. The genotypes of these SNPs were analyzed using AxiomTM genome-wide human assay. For statistical analysis we used SNPStats and Haploview version 4.2. Multiple logistic regression models (codominant, dominant, recessive and Log-additive) were produced to obtain odds ratio (OR), 95% confidence interval (CI), and p value. Results One SNP (rs11569017) in EGF gene showed significant association with ESRD but not with AR. Another SNP (rs11568835) in EGF gene showed significant association with susceptibility to AR but not with ESRD. One SNP (rs1050171) in EGFR gene showed significant association with susceptibility to AR but not with ESRD. Conclusion We suggest that genetic polymorphisms of EGF and EGFR gene may be associated with the risk of development of ESRD and AR in the Korean population.

scholarly journals Expression and distribution of epidermal growth factor in acute and chronic renal allograft rejection

1994 ◽  
Vol 46 (4) ◽  
pp. 1207-1215 ◽  
Author(s):  
Alicia N. Stein-Oakley ◽  
Alex Tzanidis ◽  
Peter J. Fuller ◽  
Paula Jablonski ◽  
Napier M. Thomson
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Allograft Rejection ◽  
Renal Allograft ◽  
Renal Allograft Rejection ◽  
Epidermal Growth

Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

2005 ◽  
Vol 23 (11) ◽  
pp. 2445-2459 ◽  
Author(s):  
José Baselga ◽  
Carlos L. Arteaga
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Egfr Gene ◽  
Epidermal Growth ◽  
Egfr Tkis ◽  
Receptor Family

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB receptor family that is abnormally activated in many epithelial tumors. The aberrant activation of the EGFR leads to enhanced proliferation and other tumor-promoting activities, which provide a strong rationale to target this receptor family. There are two classes of anti-EGFR agents: monoclonal antibodies (MAbs) directed at the extracellular domain of the receptor and small molecule, adenosine triphosphate–competitive inhibitors of the receptor's tyrosine kinase. Anti-EGFR MAbs have shown antitumor activity in advanced colorectal carcinoma, squamous cell carcinomas of the head and neck, non–small-cell lung cancer (NSCLC) and renal cell carcinomas. The tyrosine kinase inhibitors (TKIs) have a partially different activity profile. They are active against NSCLC, and a specific EGFR inhibitor has shown improvement in survival. Recently, mutations and amplifications of the EGFR gene have been identified in NSCLC and predict for enhanced sensitivity to anti-EGFR TKIs. In addition to specific anti-EGFR TKIs, there are broader acting inhibitors such as dual EGFR HER-2 inhibitors and combined anti-pan-ErbB and antivascular endothelial growth factor receptor inhibitors. Current research efforts are directed at selecting the optimal dose and schedule and identifying predictive factors of response and resistance beyond EGFR gene mutations and/or amplifications. Finally, there is a need for improved strategies to integrate anti-EGFR agents with conventional therapies and to explore combinations with other molecular targeted approaches including other antireceptor therapies, receptor-downstream signaling transduction inhibitors, and targeted approaches interfering with other essential drivers of cancer, such as angiogenesis.

Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease

2000 ◽  
Vol 36 (5) ◽  
pp. 945-952 ◽  
Author(s):  
Lorenzo S. Malatino ◽  
Francesca Mallamaci ◽  
Francesco A. Benedetto ◽  
Ignazio Bellanuova ◽  
Alessandro Cataliotti ◽  
...  
Keyword(s):  
Growth Factor ◽  
Renal Disease ◽  
Hepatocyte Growth Factor ◽  
End Stage Renal Disease ◽  
Intima Media Thickness ◽  
Media Thickness ◽  
Stage Renal Disease ◽  
End Stage ◽  
Hepatocyte Growth

Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report

Lung Cancer ◽  
2010 ◽  
Vol 68 (3) ◽  
pp. 498-500 ◽  
Author(s):  
Teruhisa Takuwa ◽  
Fumihiro Tanaka ◽  
Kazue Yoneda ◽  
Ikuko Torii ◽  
Masaki Hashimoto ◽  
...  
Keyword(s):  
Case Report ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Egfr Gene ◽  
Epidermal Growth ◽  
Gene Status ◽  
Lung Adenocarcinomas

scholarly journals Transforming growth factor-β1 hyperexpression in African American end-stage renal disease patients

1998 ◽  
Vol 53 (3) ◽  
pp. 639-644 ◽  
Author(s):  
Manikkam Suthanthiran ◽  
Ashwani Khanna ◽  
David Cukran ◽  
Rohini Adhikarla ◽  
Vijay K. Sharma ◽  
...  
Keyword(s):  
African American ◽  
Growth Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document